Skip to main content

Table 1 Patients’ characteristics

From: Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacer

Variable

23 Patients

No (%)

Age at diagnosis (years)

Range (Mean ± SD)

52–79 (66.65 ± 7.36)

Prostate volume (cc)

25.73–109.35 (60.67 ± 21.18)

PSA at diagnosis (ng/ml)

Range (Mean ± SD)

5.03–34.78 (13.1 ± 8.5)

< 10

11 (47.8%)

10–20

7 (30.4%)

> 20

5 (21.7%)

Gleason score

3 + 4

10 (43.5%)

4 + 3

5 (21.7%)

 ≥ 4 + 4

8 (34.8%)

T stage

cT2b

4 (17.4%)

cT2c

14 (60.9%)

cT3a

2 (8.7%)

cT3b

1 (4.3%)

cT4

2 (8.7%)

N Stage

N0

23 (100%)

N+

0

ADT

Yes

10 (43.5%)

No

13 (56.5%)

Hydrogel spacer

Yes

15 (65.2%)

No

8 (34.8%)

  1. PSA prostate-specific antigen, ADT androgen deprivation therapy